These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Use of immunoglobulin in severe childhood Guillain-Barré syndrome. Ortiz-Corredor F; Peña-Preciado M Acta Neurol Scand; 2007 Apr; 115(4):289-93. PubMed ID: 17376129 [TBL] [Abstract][Full Text] [Related]
6. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Korinthenberg R; Schessl J; Kirschner J; Mönting JS Pediatrics; 2005 Jul; 116(1):8-14. PubMed ID: 15995024 [TBL] [Abstract][Full Text] [Related]
7. Changes in lymphocyte subsets in patients with Guillain-Barré syndrome treated with immunoglobulin. Hou HQ; Miao J; Feng XD; Han M; Song XJ; Guo L BMC Neurol; 2014 Oct; 14():202. PubMed ID: 25315010 [TBL] [Abstract][Full Text] [Related]
8. Outcome of Guillain-Barré syndrome following intravenous immunoglobulin compared to natural course. Kalita J; Misra UK; Chaudhary SK; Das M; Mishra A; Ranjan A; Kumar M Eur J Neurol; 2022 Oct; 29(10):3071-3080. PubMed ID: 35837807 [TBL] [Abstract][Full Text] [Related]
9. Treatment of childhood acute immune thrombocytopenic purpura with high-dose methylprednisolone, intravenous immunoglobulin, or the combination of both. Gereige RS; Barrios NJ P R Health Sci J; 2000 Mar; 19(1):15-8. PubMed ID: 10761200 [TBL] [Abstract][Full Text] [Related]
10. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS). van Doorn PA Presse Med; 2013 Jun; 42(6 Pt 2):e193-201. PubMed ID: 23628447 [TBL] [Abstract][Full Text] [Related]
12. Electrophysiological subtypes and prognosis of childhood Guillain-Barré syndrome in Japan. Nagasawa K; Kuwabara S; Misawa S; Fujii K; Tanabe Y; Yuki N; Hattori T; Kohno Y Muscle Nerve; 2006 Jun; 33(6):766-70. PubMed ID: 16506153 [TBL] [Abstract][Full Text] [Related]
13. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. van Koningsveld R; Schmitz PI; Meché FG; Visser LH; Meulstee J; van Doorn PA; Lancet; 2004 Jan; 363(9404):192-6. PubMed ID: 14738791 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Kuitwaard K; de Gelder J; Tio-Gillen AP; Hop WC; van Gelder T; van Toorenenbergen AW; van Doorn PA; Jacobs BC Ann Neurol; 2009 Nov; 66(5):597-603. PubMed ID: 19938102 [TBL] [Abstract][Full Text] [Related]
15. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. The Dutch Guillain-Barré Study Group. Ann Neurol; 1994 Jun; 35(6):749-52. PubMed ID: 8210234 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of intravenous immunoglobulin retreatment amongst Guillain-Barré syndrome patients who poorly responded to initial IVIG cycle: a systematic review. Prado MB; Adiao KJB; Turalde CWR; Dasig DA Acta Neurol Belg; 2024 Aug; 124(4):1237-1250. PubMed ID: 38553651 [TBL] [Abstract][Full Text] [Related]